A Structurally Distinctive Library for High-Quality Hit Discovery
SymeGold, developed by Symeres, is a 78,000-compound screening library designed to offer structural diversity, synthetic tractability, and physicochemical robustness that aren’t available in existing commercial libraries—key criteria that go beyond library size alone. Originally initiated as part of the European Lead Factory (ELF) initiative, SymeGold has evolved into a modular and expandable platform that prioritizes medicinal chemistry relevance and novel scaffold design. An additional 10,000 compounds are projected to be added by the end of 2025, building on its foundational principles. We also offer high-throughput screening services with our strategic partner, Axxam S.p.A.
The SymeGold library was founded on six key principles: novelty, chemical tractability, structural integrity, physicochemical properties, innovation, and diversification potential. These design principles ensure a unique, high-quality collection for high-throughput screening.
SymeGold Modalities
The SymeGold collection includes diverse chemotypes, such as spirocyclic compounds, pseudo-natural products, and macrocyclic compounds.
Spirocyclic molecules: Limit the number of sp2 rich molecules. The SymeGold library addresses this by featuring 27,000 spirocyclic scaffolds, to avoid ‘molecular flatland’.
Pseudo Natural Compounds: SymeGold includes 4,000 pseudo-natural compounds, which utilize natural products as starting points for the generation of novel scaffolds
Macrocyclic Molecules: SymeGold incorporates 1,900 macrocyclic molecules that are now also available as a separate subset named SymeCycle.
Properties
SymeGold compounds are enumerated to capture key medicinal chemistry attributes such as cLogP, polar surface area, molecular weight, aromatic rings, and MPO score.
SymeCycle – Macrocyclic subset
SymeCycle, a subcollection of the SymeGold collection, is a growing set of macrocyclic compounds. Currently encompassing 1,900 compounds, it is expected to reach 2,500 by the end of 2025. Our macrocyclic derivatives have molecular weights up to 640 daltons and lipophilicity values ranging from -2.5 to 5.2.
HTS Access and Screening Collaboration
While Symeres focuses on compound design and chemistry, HTS campaigns using SymeGold are conducted in collaboration with Axxam S.p.A., a leader in assay development and high-throughput screening. Screening options include:
- Transfer of validated assays to Axxam’s platform
- Use of existing assay formats
- Integration with Axxam’s other collections (e.g. AXXDiversity, RNA-targeting libraries)
Rapid validation and follow-up research are supported by the option to order selected compounds from SymeGold’s powder stock or through de novo synthesis using key building blocks.
Compound availability: Powder aliquots of SymeGold compounds are stored at -20°C at Symeres’ research site with a two-week turnaround time for orders.
Key Building Blocks: Essential components for most scaffolds are readily available for rapid resynthesis and preparation of additional analogues.
SymeGold is managed for ease of access, reusability, and scale-up, ensuring that promising hits can be rapidly advanced into medicinal chemistry workflows.
Learn more or access the collection:
To explore how SymeGold can enhance your screening campaign, or to initiate a collaborative screening project, please contact:
